Welcome to our dedicated page for Intercure news (Ticker: INCR), a resource for investors and traders seeking the latest updates and insights on Intercure stock.
InterCure Ltd. reports developments for a medical cannabis company operating as Canndoc, with activities in research, cultivation, production and distribution of pharmaceutical-grade cannabis products. Company updates commonly cover financial results, Adjusted EBITDA, operating cash flow, recovery of production and sales after damage to its southern facility, and the role of Canndoc as a licensed Israeli cannabis producer with GMP-certified products.
News also includes international market activity and partnerships, including German market revenue and brand collaborations, as well as cannabis regulatory developments in the United States and Europe. Corporate items include Nasdaq minimum bid compliance, ordinary-share capital actions, annual meeting matters, material agreements and board leadership changes.
InterCure (NASDAQ: INCR) reported FY2025 results: revenue of NIS 270.2 million, net loss of NIS 36.8 million, Adjusted EBITDA of NIS 46.6 million and positive operating cash flow of NIS 17 million. The company resumed production at Nir Oz, launched 75+ GMP SKUs, completed strategic deals including the Botanico purchase and a Cannasoul investment, received NIS 82 million in compensation advances, and held NIS 49 million cash at year-end.
The release notes continued recovery from the October 7, 2023 events and expanding revenues in Germany, with Botanico expected to contribute >NIS 30 million in H2 2026.
InterCure (Nasdaq: INCR) received a Nasdaq notice on February 25, 2026 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5450(a)(2).
The company has a 180-calendar day compliance period until August 24, 2026 to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. InterCure may seek an additional 180-day period by submitting a transfer application and intends to consider a reverse share split as part of its compliance plan.
InterCure (Nasdaq: INCR) reported preliminary 2025 results with estimated NIS 265 million revenue, roughly +11% vs. 2024, and positive Adjusted EBITDA for both halves (twelfth consecutive positive half). The company ended 2025 with NIS 43 million cash and nearly 20% H2 revenue growth, plus first significant German revenues.
Key actions include resumed Nir Oz production, >70 new GMP SKUs, an agreed acquisition of Botanico, a 28% Cannasoul stake, and NIS 81 million in compensation advances (NIS 251 million claim submitted).
InterCure (Nasdaq: INCR) entered a definitive Share Purchase Agreement and Collaboration Agreement with Cannasoul on Nov 3, 2025, taking a 28% ownership stake on a fully diluted basis and an exclusive path to 51% within two years.
The Collaboration Agreement formalizes joint research, development, and commercialization of evidence-based cannabis therapeutics and anticipates Prof. Dedi Meiri joining as Chair of an InterCure Scientific Advisory Board to accelerate R&D integration.
The transaction is subject to customary closing conditions and regulatory approvals; the release notes potential U.S. market opportunities tied to reported federal rescheduling discussions.
InterCure (NASDAQ: INCR) reported first half 2025 results: NIS 130 million revenue, NIS 12.6 million Adjusted EBITDA (10% margin) and NIS 12 million positive operating cash flow. Revenue rose 15% versus H2 2024 and 3% year‑over‑year. Net loss was NIS 1.8 million. Cash on hand improved to NIS 54 million from NIS 21 million a year earlier. The company resumed production at its Nir Oz facility, launched 40+ SKUs, received NIS 81 million in compensation advances against submitted damages of NIS 251 million, and signed a share purchase agreement to acquire ISHI to expand U.S. genetics and supply.
InterCure (NASDAQ: INCR) has announced the strategic acquisition of Botanico Ltd. (ISHI), a premium cannabis technology and brand company. The transaction will be executed in two phases, with InterCure acquiring 100% of ISHI for 4,924,261 ordinary shares, representing approximately 10% of InterCure's fully diluted shares.
The acquisition provides InterCure immediate access to advanced cultivation technologies, exclusive partnerships with leading U.S. cannabis operators including The Flowery, and premium American genetics. The deal comes amid potential cannabis rescheduling from Schedule I to Schedule III by the Trump administration, positioning InterCure to capitalize on evolving U.S. market opportunities.
The transaction is expected to close in Q1 2026, subject to regulatory approvals. ISHI's leadership team, including CEO Omer Layani and COO Dor Hershkovitz, will join InterCure's management. The acquisition is projected to be accretive within the first year.
InterCure (NASDAQ: INCR) announced leadership changes and financing updates. Ehud Barak will step down as Chairman effective February 13, 2025, to be succeeded by current CEO Alexander Rabinovich, who has led the company's growth over the past five years.
The company successfully completed a financing round of NIS 66 million (approximately $18.2 million) to support the recovery of the Nir Oz Facility, with potential additional proceeds of up to NIS 107 million ($29.8 million) through warrant exercises. The funding includes investments from key shareholders and a loan agreement with a leading Israeli bank.
InterCure is executing its war recovery plan following the October 7, 2023 events that impacted its Nir Oz facility. The company expects additional compensation from Israeli authorities for war-related damages and is focused on rebuilding its pharmaceutical cannabis portfolio while expanding operations in Germany, the UK, and Australia.
InterCure (NASDAQ: INCR) has secured funding commitments of NIS 66 million (USD 18.2M), potentially increasing to NIS 107 million (USD 29.8M), to support the recovery of its Nir Oz facility damaged during the war. The funding includes a private placement with key investors, including CEO Alexander Rabinovich and shareholders Yaron Yakobi and Tzahi Hagag, who will each hold over 5% stake. The placement involves issuing 7,349,896 ordinary shares at NIS 4.83 per share and warrants for additional shares at NIS 5.70.
Additionally, the company secured a NIS 30 million (USD 8.3M) loan from a leading Israeli bank. InterCure expects to receive substantial compensation from Israeli authorities for war-related damages and plans to expand its facility post-war in collaboration with the Tkumah administration.
InterCure (NASDAQ: INCR) reported its financial results for the first half of 2024, with revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million (17% of revenues). The company achieved its 16th and 17th consecutive quarters of profitability despite challenges from the October 7, 2023 terrorist attack and the war in Gaza. InterCure is receiving compensation from Israeli authorities for damages to its Southern Facility.
The company announced an expansion of its partnership with Cookies™ to Germany, expecting to launch products there in Q4 2024. InterCure anticipates double-digit growth in the second half of 2024 due to expected launches in German and UK markets. The company continues to expand its medical cannabis pharmacy chain, now with 24 active locations.